Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).

NCT Number	NCT07007273
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Merck Sharp & Dohme LLC
Conditions	Cutaneous Sarcoma
Enrollment	17 participants
Start Date	2025-06-20
Primary Completion	2030-07 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-01